Templeton, ICICI’s Bet on Indian Pharmaceuticals Is Paying OffBy and
ICICI Prudential overweight on drugmakers on improving outlook
Antique prefers large pharma on under-ownership, generics push
India’s pharmaceutical industry is helping lead an equity bull run as investors wager on a resolution to U.S. regulatory sanctions that rocked companies in the sector last year.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.